BioSpyder Technologies

BioSpyder Technologies, founded in 2010 and headquartered in Carlsbad, California, commercializes the TempO-Seq™ platform, a novel targeted RNA sequencing assay. The technology differentiates itself by enabling direct analysis from crude lysates, offering high sensitivity down to 10pg input, and allowing massive sample multiplexing, which dramatically reduces per-sample cost and complexity. This positions the company as an enabler for large-scale, high-throughput transcriptomic studies in both research and potential diagnostic applications. The business model appears to be a mix of platform technology (assay kits/panels) and fee-for-service bioinformatics and sequencing services.

TempO-Seq™ (Templated Oligo-Sequencing): A targeted, hybridization and ligation-based NGS assay that converts RNA targets directly into sequencing barcodes. It enables high-throughput, multiplexed gene expression profiling from minimal input (down to 10pg) and diverse sample types (lysates, FFPE, blood spots) without RNA extraction or cDNA synthesis.

BioSpyder competes with broad NGS-based RNA-Seq services (Illumina, Azenta), targeted gene expression panels (NanoString's nCounter, Thermo Fisher's TaqMan), and high-throughput qPCR. Its differentiation is the unique combination of direct sample analysis, extreme multiplexing capability, and flexible panel design without proprietary instrumentation.